NCT01727778View on ClinicalTrials.gov

Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Drug Safety
Interventions
BIOLOGICAL

Anti-GRP78 monoclonal IgM antibody PAT-SM6

Trial Locations (1)

97080

Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg

Sponsors

Lead Sponsor

Patrys Ltd.
All Listed Sponsors
lead

Patrys Ltd.

INDUSTRY

NCT01727778 - Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter